ClinicalTrials.gg
RecruitingNCT05830136Updated Nov 12, 2024

Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy

An interventional study of sodium bicarbonate Ringer's solution in Hepatic Ischemia, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Feb 2022, registered Feb 2023).
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Ischemia with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Ischemia · China.

Planned enrollment
23rd of 34
100 · median 172
Started
2022
with 1 other
No phase
19 of 39
3 open now
Registered
34th of 39
by date

Among the 39 studies in Ischemia with a site in China, this one is the 23rd largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2022, is one of 19 with no phase, and was the 34th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

4 of the 39 studies in Ischemia with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Ischemia with a site in China, or all of them as a file.
02

Study summary

Compared the effects of Sodium bicarbonate Ringer's solution and lactate Ringer's solution on the internal environment and hemodynamics of patients during laparoscopic liver resection, to observe the application prospect of sodium bicarbonate Ringer's solution in Laparoscopic hepatectomy.

Read the detailed description

The study was a single-center prospective randomized controlled study. A total of 100 patients undergoing laparoscopic hepatectomy under general anesthesia were randomly divided into 2 groups: Group A, sodium bicarbonate Ringer's solution group(n=50); Group B, Lactate Ringer's solution group (intraoperative crystal fluid dilatation was lactate ringer's injection, n=50); Collect patients' arterial blood gas, blood pressure, heart rate, peripheral vascular resistance, heart rate, blood vessels, the active drug usage, 5% sodium bicarbonate injection usage, inflammation factors, transaminase, creatinine, etc. with the point of preoperative (T0), during liver specimens resected(T1), after liver specimens resected(T2), and the end of surgery (T3). Then statistical analysis and observe the application prospect of sodium bicarbonate Ringer's injection in Laparoscopic hepatectomy.

03

Conditions studied

  • Hepatic Ischemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old,
  2. patients who plan to undergoing laparoscopic hepatectomy ;
  3. Willing to sign .

Exclusion criteria

Exclusion Criteria:

  1. age \<18 years
  2. pregnancy
  3. active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure)
  4. history of significant cerebrovascular disease
  5. restrictive or obstructive pulmonary disease
  6. uncontrolled hypertension
  7. renal dysfunction ( \<60 mL/min),
  8. evidence of hepatic metabolic disorder ( >35 mmol/L)
  9. presence of active infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Group A

    Sodium bicarbonate Ringer's solution group

    Drug: sodium bicarbonate Ringer's solution

  • Active comparator
    Group B

    Lactate Ringer's solution group

    Drug: sodium bicarbonate Ringer's solution

Interventions

  • DrugRinger's LactateStudies of Ringer's LactateRinger's Lactate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.

    Also known as: lactated Ringer's solution

06

What researchers measure

Primary outcomes

  1. lactic values

    to compare the conditions of acid-base balance and internal environment between the two groups

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

Secondary outcomes

  1. Amount of sodium bicarbonate injection (ml)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

  2. Value of pH

    Time frame: From the start of operation until the end of operation (during the operation).

  3. Concentration of HCO3-

    Time frame: From the start of operation until the end of operation (during the operation).

  4. Value of BE

    Time frame: From the start of operation until the end of operation (during the operation).

  5. Concentration of Glucose

    Time frame: From the start of operation until the end of operation (during the operation).

  6. Value of MAP

    Time frame: From the start of operation until the end of operation (during the operation).

  7. Value of HR

    Time frame: From the start of operation until the end of operation (during the operation).

  8. Concentration of CI

    Time frame: From the start of operation until the end of operation (during the operation).

  9. Value of SVV

    Time frame: From the start of operation until the end of operation (during the operation).

  10. Value of SVR

    Time frame: From the start of operation until the end of operation (during the operation).

  11. Value of PPV

    Time frame: From the start of operation until the end of operation (during the operation).

  12. Amount of norepinephrine

    Time frame: From the start of operation until the end of operation (during the operation).

  13. Amount of phenylephrine

    Time frame: From the start of operation until the end of operation (during the operation).

  14. Amount of ephedrine

    Time frame: From the start of operation until the end of operation (during the operation).

  15. Amount of nitroglycerin

    Time frame: From the start of operation until the end of operation (during the operation).

  16. Amount of milrinone

    Time frame: From the start of operation until the end of operation (during the operation).

  17. Amount of furosemide

    Time frame: From the start of operation until the end of operation (during the operation).

  18. time of palinesthesia from general anesthsia

    postoperative palinesthesia, recovering time

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

  19. time of stay in PACU

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

  20. extubation time

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month.

  21. Concentration of BUN

    Time frame: day 1 and day 3 after surgery.

  22. Concentration of Cr

    Time frame: day 1 and day 3 after surgery.

  23. Value of AST

    Time frame: day 1 and day 3 after surgery.

  24. Value of ALT

    Time frame: day 1 and day 3 after surgery.

  25. Amount of blood loss

    amount of blood loss during the operation.

    Time frame: intraoperative

  26. Amount of blood transfusion

    amount of blood transfusion during the operation.

    Time frame: intraoperative

  27. urinary output

    amount of urinary output during the operation.

    Time frame: intraoperative

  28. 15-item quality of recovery scale scores (QoR-15)

    15-item quality of recovery scale scores. the minimum value is 0 and maximum value is 150, and whether higher scores mean a better outcome.

    Time frame: day 1 and day 3 after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2026, 47 months after the start.

Of 72 non-industry interventional studies with no phase under Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 47 months is above that.

Counting every sponsor, half of 83 studies reached it within 31 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Apr 26, 2023
StartActual
Feb 1, 2022
Primary completionEst.
Jan 1, 2026
CompletionEst.
May 1, 2026
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05830136
Responsible party
Shijiang Liu, MD (Clinical Professor, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Apr 26, 2023
Start date
Feb 1, 2022
Primary completion
Jan 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Nov 12, 2024

Study contacts

Shijiang Liu
Contact
liushijiang@jsph.org.cn
02568303569
Shijiang Liu
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ringer's Lactate

Start the discussion